Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8131 to 8145 of 8216 results

  1. Insulin icodec for treating type 1 and type 2 diabetes ID6175

    In development [GID-TA11104] Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Adrenal insufficiency: identification and management

    In development [GID-NG10237] Expected publication date: 28 August 2024

    NICE guideline
    In development

  3. Children and young people with disabilities and severe complex needs: integrated health and social care support

    Awaiting development [GID-QS10146] Expected publication date: TBC

    Quality standard
    Awaiting development

  4. Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care

    Awaiting development [GID-QS10144] Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Pelvic floor dysfunction

    Awaiting development [GID-QS10129] Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Transcatheter aortic valve implantation for aortic incompetence

    Awaiting development [GID-IPG10357] Expected publication date: 11 June 2025

    Interventional procedures guidance
    Awaiting development

  7. Vibostolimab–pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6382]

    Awaiting development [GID-TA11466] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Tiragolumab with atezolizumab for treating locally advanced unresectable stage 3 non-small-cell lung cancer after at least 2 cycles of platinum-based chemoradiation [ID6250]

    Awaiting development [GID-TA11278] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Guselkumab for treating moderately to severely active ulcerative colitis ID6237

    In development [GID-TA11247] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Guselkumab for previously treated moderately to severely active Crohn's disease ID6238

    In development [GID-TA11245] Expected publication date: TBC

    Technology appraisal guidance
    In development

  11. Novel home-testing devices for diagnosing obstructive sleep apnoea/hypopnoea syndrome

    In development [GID-DG10074] Expected publication date: 11 September 2024

    Diagnostics guidance
    In development

  12. Fidanacogene elaparvovec for treating moderately severe to severe haemophilia B [ID4032]

    In development [GID-TA11117] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  13. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  14. Basal insulin icodec–semaglutide for treating type 2 diabetes inadequately controlled with daily basal insulin TSID 11940

      Status ...

    Technology appraisal guidance
    Topic selection

  15. Belantamab mafodotin with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma after 1 or more treatments ID6211

    In development [GID-TA11201] Expected publication date: TBC

    Technology appraisal guidance
    In development